JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

A retrospective analysis of tissue, liquid, and germline testing in Hispanic and non-Hispanic men with advanced hormone-sensitive prostate cancer

  • 0Department of Medicine, University of Arizona, Tucson, AZ.
Urologic Oncology +

|

March 2, 2025

|

March 2, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Hispanic American men with prostate cancer (PCa) present with more advanced disease and distinct genomic mutations, including TMPRSS2-ERG fusion and TMB-High. These findings underscore the need for tailored screening and treatment strategies for this underrepresented group.

Area Of Science

  • Oncology
  • Genomics
  • Health Disparities

Background

  • Prostate cancer (PCa) significantly impacts American men, with notable racial and ethnic disparities.
  • Hispanic Americans (HAs) are underrepresented in PCa genomic research despite their disease burden.

Purpose Of The Study

  • To investigate genomic differences in prostate cancer between Hispanic Americans (HAs) and Non-Hispanics (NHs).
  • To understand the drivers of health disparities in PCa within the underrepresented HA population.

Main Methods

  • Retrospective analysis of 111 metastatic prostate adenocarcinoma patients (2015-2023).
  • Genomic data from tissue, liquid, and germline samples compared between HA and NH patient cohorts.
  • Statistical analysis included t-tests, Kruskal-Wallis, Chi-square, Fisher's exact tests, and Kaplan-Meier methods.

Main Results

  • Hispanic Americans (HAs) represented 41% of the study cohort.
  • HAs exhibited higher PSA levels, more advanced pathological stages (T4, M1c), and shorter time to first-line treatment.
  • TMPRSS2-ERG fusion and TMB-High mutations were significantly more prevalent in HAs.

Conclusions

  • Hispanic American PCa patients present with more advanced disease compared to Non-Hispanics.
  • Genomic disparities, including TMPRSS2-ERG fusion and TMB-High mutations, necessitate early detection and personalized treatments for HAs.
  • Expanding genomic research and addressing treatment disparities are critical for improving outcomes in this underrepresented population.

Keywords: